Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 double-blind, placebo-controlled of EB06 in adults with moderate to severe non-segmental (generalized) vitiligo

Next Previous
Search
Trial Profile

Phase 2 double-blind, placebo-controlled of EB06 in adults with moderate to severe non-segmental (generalized) vitiligo

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NI 0801 (Primary)
  • Indications Vitiligo
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Feb 2025 According to a Edesa Biotech media release, data anticipated to be submitted to regulators at the U.S. Food and Drug Administration (FDA) during the middle of 2025. The company intends to pursue an investigational new drug (IND) application for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients. Edesa anticipates topline results could be available within as few as 12 to 18 months following regulatory clearance by the FDA.
    • 13 Feb 2025 According to a Edesa Biotech media release, the company currently expects to use the net proceeds from the offering of approximately $15.0 million through the sale of Series B-1 Preferred Shares and common shares, to fund the continued advancement of EB06, its CXCL10 monoclonal antibody, into a Phase 2 clinical study in subjects with nonsegmental vitiligo, and for working capital and general corporate purposes.
    • 14 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top